Table 1.
Demographic covariates for the study patients (n = 86)
| Baseline covariate | |
|---|---|
| Sex, n (%) | |
| • Male | 54 (62.8%) |
| • Female | 32 (37.2%) |
| Age (years) | |
| • Mean ± SD | 53.1 ± 13.8 |
| Body surface area (m2) | |
| • Mean ± SD | 1.97 ± 0.26 |
| NCCTG study, n (%) | |
| • 96-72-51 | 56 (65.1%) |
| • N997D | 30 (34.9%) |
| ECOG performance status, n (%) | |
| • 0 | 28 (32.6%) |
| • 1 | 42 (48.8%) |
| • 2 | 16 (18.6%) |
| Grade of disease, n (%) | |
| • 1 | 1 (1.1%) |
| • 2 | 16 (18.6%) |
| • 3 | 8 (9.3%) |
| • 4 | 58 (67.4%) |
| • Unknown | 3 (3.4%) |
| Concomitant corticosteroid, n (%) | |
| • Yes | 67 (77.9%) |
| • No | 19 (22.1%) |
| Concomitant EIAED, n (%) | |
| • Yes | 56 (65.1%) |
| • No | 30 (34.9%) |
| EIAED type, n (%) | |
| • None/non-inducing AED | 30 (34.9%) |
| • Phenytoin | 36 (41.9%) |
| • Carbamazepine | 9 (10.5%) |
| • Phenobarbital | 3 (3.5%) |
| • 2 or more EIAEDs | 8 (9.3%) |
| Dose level, n (%) | |
| • 100 mg/m2 | 19 (22.1%) |
| • 125 mg/m2 | 26 (30.2%) |
| • 250 mg/m2 | 23 (26.7%) |
| • 300 mg/m2 | 6 (7.0%) |
| •400 mg/m2 | 12 (14.0%) |